Sign in
Taking people in United StatesNo phase

Tracks pregnancy and infant outcomes after ubrogepant or atogepant use

Follows pregnant women with migraine who take ubrogepant or atogepant.

Key facts

Who runs it
AbbVie
Where
Durham, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
Status
Recruiting
People taking part
1,884 people, planned
Started
10 Jan 2023
Expected to end
Jan 2036
Type of study
Observational, 3 groups
Record updated
15 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with migraine in the United States or Canada. Some took Ubrelvy or Qulipta during pregnancy, others did not.

Age
18 years or older
Sex
Women only
Disease stage
Migraine diagnosed by the patient's health care provider
Earlier treatment
Three groups: took at least 1 dose of Ubrelvy during pregnancy; took at least 1 dose of Qulipta during pregnancy; or never took Ubrelvy or Qulipta, or stopped Ubrelvy 2 days or Qulipta 5 days before conception.

Main reasons for not taking part

  • Took any other gepant or CGRP monoclonal antibody before conception or during pregnancy before enrollment
  • No longer pregnant when enrolling (the pregnancy has already ended and the outcome is known)

This trial only enrols pregnant participants. The registry sentence this rests on: Qualify as a prospective enrollment, defined as currently pregnant.

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Within the United States or Canada
  • Qualify as a prospective enrollment, defined as currently pregnant
  • A diagnosis of migraine by the patient's health care provider (HCP)
  • Provide contact information for the participant and her and her infant(s)', if applicable, HCPs
  • Authorize their HCP(s) to release maternal and infant medical information to the registry, upon request
  • Provide sufficient information to confirm eligibility for 1 of following:; Ubrelvy-exposed women with migraine: documented information indicating that at least 1 dose of Ubrelvy was taken during pregnancy, including the estimated number of administrations per trimester; Qulipta-exposed women with migraine: documented information to indicating that at least 1 dose of Qulipta was taken during pregnancy, including start and stop date(s) of administration; Internal comparator: Ubrelvy/Qulipta-unexposed pregnant women with migraine: documented information indicating that they have, a) never taken Ubrelvy and/or Qulipta, or b) discontinued Ubrelvy 2 days prior or Qulipta 5 days prior to conception

Who cannot take part

  • Documentation of exposure to any gepants (acute or preventive) other than Ubrelvy and Qulipta, or CGRP monoclonal antibodies, from 5 halflives of the respective treatment prior to conception or at any point during pregnancy before enrollment
  • Women who are no longer pregnant (retrospective cases women for whom the pregnancy has already ended, and the outcome of pregnancy is known at the time of enrollment)
  • For further clarification of inclusion/exclusion please contact the investigator to the end of this section in case anything is unclear to a potential patient, etc

Where in United States

Also in 1 other country, 1 site

  • IqviaDurham, United StatesTaking people

About the trial

What the trial wants to find out

Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity. The purpose of this study is to evaluate fetal, maternal, and infant outcomes through 12 months of age among women exposed to Ubrelvy or Qulipta during pregnancy, as well as in 2 comparator groups.

Read full original descriptionShow less

Ubrelvy (ubrogepant) and Qulipta (atogepant) are approved drugs for the acute treatment of migraine in adults. Approximately 628 pregnant women with migraine exposed to Ubrelvy, 628 pregnant women with migraine exposed to Qulipta and 628 pregnant women with migraine in comparator group will be enrolled in this study in the United States.

Participants enrolled in the Ubrelvy-exposed group and Qulipta-exposed group will receive Ubrelvy and Qulipta respectively as prescribed by their physician.

The 3 groups in the trial

  • Ubrelvy-Exposed Women With Migraine

    Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.

  • Qulipta-Exposed Women With Migraine

    Pregnant women with migraine who took at least 1 dose of Qulipta, the exposure of interest, at any time during pregnancy as part of routine care.

  • Ubrelvy/Qulipta-Unexposed Women With Migraine

    Pregnant women with migraine who have never taken Ubrelvy and/or Qulipta, OR discontinued Ubrelvy 2 days prior or Qulipta 5 days prior to conception.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Ubrelvy and Qulipta Pregnancy Exposure Registry EMPRESS: An Observational, Prospective Study to Assess the Safety of Ubrelvy (Ubrogepant) and Qulipta (Atogepant) During Pregnancy
Plain-language title
Tracks pregnancy and infant outcomes after ubrogepant or atogepant useGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 December 2025